Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

作者
Satoshi Endo,Hisao Imai,Atsuto Mouri,Kasumi Tsukamoto,Kenji Masaki,Kosuke Hashimoto,Yu Miura,Ayako Shiono,Ou Yamaguchi,Junichi Nakagawa,Kyoichi Kaira,Kunihiko Kobayashi,Hiroshi Kagamu
出处
期刊:Journal of Cancer Research and Clinical Oncology [Springer Science+Business Media]
卷期号:151 (1): 43-43 被引量:2
标识
DOI:10.1007/s00432-025-06089-x
摘要

PURPOSE: Nivolumab plus ipilimumab (Nivo-Ipi) combination therapy is an effective first-line treatment for advanced non-small cell lung cancer (NSCLC). However, its effectiveness and feasibility in elderly patients (aged ≥ 75 years) remain unclear. This study aimed to investigate the efficacy and safety of first-line Nivo-Ipi therapy in elderly patients with NSCLC. METHODS: This retrospective study included 57 patients with NSCLC (52 men and 5 women), aged ≥ 75 years (range: 75-86) who received first-line Nivo-Ipi therapy from December 2020 to November 2022 at four institutes in Japan. Patient characteristics, therapeutic efficacy, and the incidence and severity of adverse events (AE) were assessed. RESULTS: The overall response rate was 42.1%, the disease control rate was 73.6%, the median progression-free survival (PFS) was 7.1 months, and the median overall survival (OS) was 14.1 months. Common Grade ≥ 3 AEs included pneumonitis, elevated aspartate transaminase, elevated alanine transaminase, adrenal insufficiency, and colitis. No treatment-related deaths were reported. PFS and OS were longer in patients who experienced treatment-related AEs. Patients with and without AEs had a median PFS of 11.7 and 2.8 months, respectively. Similarly, the median OS of patients with and without AEs was 20.4 and 9.0 months, respectively. CONCLUSION: First-line Nivo-Ipi therapy is effective in elderly patients with NSCLC. Although there was an increased incidence of pneumonitis, the treatment was manageable and presented as a viable treatment option. Notably, the occurrence of treatment-related AEs was associated with improved clinical outcomes, suggesting a potential prognostic value of AEs in this population.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
七七八八完成签到 ,获得积分10
1秒前
杨丽完成签到,获得积分10
1秒前
橘子完成签到,获得积分10
2秒前
yu完成签到,获得积分10
2秒前
碳烤小肥羊完成签到 ,获得积分10
2秒前
愤怒的雁梅完成签到,获得积分10
2秒前
细心珊完成签到,获得积分10
2秒前
彭于晏的应助被猛犸象冲冲冲采纳,获得10
2秒前
端庄的萝发布了新的文献求助10
2秒前
lllxxx发布了新的文献求助10
3秒前
3秒前
3秒前
充电宝的应助被炼丹炉采纳,获得10
3秒前
3秒前
小森林发布了新的文献求助10
3秒前
句故完成签到,获得积分10
3秒前
碧蓝中恶完成签到,获得积分10
3秒前
天天快乐的应助被真三采纳,获得10
3秒前
3秒前
4秒前
传奇3的应助被王达采纳,获得10
4秒前
Jing完成签到 ,获得积分10
4秒前
小春日和完成签到,获得积分10
4秒前
Li完成签到,获得积分10
4秒前
宫碧空发布了新的文献求助10
4秒前
757龙发布了新的文献求助20
4秒前
04d的应助被Suyg采纳,获得10
6秒前
6秒前
世界和我完成签到 ,获得积分10
6秒前
7秒前
鲸落小小的应助被内向百川采纳,获得10
7秒前
粗心的哑铃完成签到,获得积分10
7秒前
青麋完成签到,获得积分10
7秒前
Garland完成签到,获得积分10
7秒前
NexusExplorer的应助被杨媛采纳,获得10
7秒前
Carol完成签到,获得积分10
7秒前
Jasper的应助被zgw采纳,获得10
7秒前
Xxxxxxx完成签到,获得积分10
7秒前
米斯塔林完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162